Jump Financial’s Rhythm Pharmaceuticals RYTM Stock Holding History

Jump Financial’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-6,759	Closed	-$723K	–	2338
2025 Q4	$723K	Buy	+6,759	New	+$717K	0.01%	1124
2025 Q3	–	Sell	-17,671	Closed	-$1.12M	–	2171
2025 Q2	$1.12M	Sell	17,671 -24,089	-58%	-$1.47M	0.01%	934
2025 Q1	$2.21M	Buy	+41,760	New	+$2.32M	0.03%	551
2024 Q4	–	Sell	-13,716	Closed	-$719K	–	1954
2024 Q3	$719K	Buy	+13,716	New	+$657K	0.01%	956
2024 Q1	–	Sell	-12,793	Closed	-$588K	–	2248
2023 Q4	$588K	Buy	+12,793	New	+$404K	0.02%	972
2023 Q2	–	Sell	-11,618	Closed	-$207K	–	2116
2023 Q1	$207K	Buy	+11,618	New	+$292K	0.01%	1301
2022 Q2	–	Sell	-27,500	Closed	-$317K	–	1972
2022 Q1	$317K	Buy	+27,500	New	+$241K	0.01%	1042
2020 Q4	–	Sell	-10,841	Closed	-$235K	–	1152
2020 Q3	$235K	Buy	+10,841	New	+$249K	0.05%	584

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jump Financial's RYTM Position: Q1 2026 in Review

Jump Financial sold out of Rhythm Pharmaceuticals (RYTM) in Q1 2026, closing a stake of 6,759 shares — an estimated $723K sold.

Jump Financial first reported a position in RYTM in Q3 2020 and held it in 8 quarters. The position peaked at $2.21M in Q1 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

Jump Financial reported no remaining Rhythm Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Jump Financial sold 6,759 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $723K.
Jump Financial first reported a position in Rhythm Pharmaceuticals in Q3 2020 and held it in 8 quarters.
Jump Financial's Rhythm Pharmaceuticals position peaked at $2.21M in Q1 2025.
285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Jump Financial's 13F filing for Q1 2026, filed 14 May 2026.